Watch HUMAW. Know when insiders buy.
One email the day a filing lands. Free.
HUMAW
Humacyte, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
81
PASS · shorts 81
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $2.1M +159.3%NET INCOME −$96.7MNET CASH $43.6M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $406K | +34.9% | -203.2% | −$27M | −$36.8M | — | -0.16 | −$22.1M | $104K | −$22.2M | Aug 12 |
| Q1 2026 · Mar 31 | $495K | −4.3% | -311.7% | −$28.9M | −$17.6M | −145.0% | -0.09 | −$25.1M | $175K | −$25.3M | Aug 12 |
| Q4 2025 · Dec 31derived | $467K | — | -1844.8% | −$30.8M | −$24.8M | — | -0.15 | −$26.1M | $39K | −$26.2M | Mar 27 |
| Q3 2025 · Sep 30 | $753K | — | 65.5% | −$24.4M | −$17.5M | — | -0.11 | −$23.9M | $49K | −$24M | Nov 12 |
| Q2 2025 · Jun 30 | $301K | — | 29.2% | −$29.7M | −$37.7M | — | -0.24 | −$26.4M | $568K | −$27M | Aug 12 |
| Q1 2025 · Mar 31 | $517K | — | 71.6% | −$23.2M | $39.1M | — | 0.28 | −$28.6M | $228K | −$28.8M | Aug 12 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$28.1M | −$20.9M | — | -0.16 | −$26.6M | $63K | −$26.6M | Mar 27 |
| Q3 2024 · Sep 30 | $0 | — | — | −$30.2M | −$39.2M | — | -0.33 | −$22.9M | $934K | −$23.8M | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$29.5M | −$56.7M | — | -0.48 | −$21.3M | $184K | −$21.5M | Nov 12 |
| Q1 2024 · Mar 31 | $0 | — | — | −$26.6M | −$31.9M | — | -0.29 | −$27.3M | $391K | −$27.7M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$26.2M | −$25.1M | — | -0.24 | −$19.1M | $150K | −$19.2M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$24.6M | −$26M | — | -0.25 | −$13M | $493K | −$13.5M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2M | -376.1% | −$108.1M | −$40.8M | -2003.6% | -0.26 | −$105M | $884K | −$105.9M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$114.4M | −$148.7M | — | -1.26 | −$98.1M | $1.6M | −$99.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$100M | −$110.8M | — | -1.07 | −$73.3M | $2.3M | −$75.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$84.6M | −$12M | — | -0.12 | −$71.1M | $1M | −$72.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$81.2M | −$26.5M | — | -0.66 | −$81.2M | $220K | −$81.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$64.6M | −$66.5M | — | -11.54 | −$55.6M | $318K | −$55.9M | — | — |
Every number comes from Humacyte, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.